|
Market Closed -
Japan Exchange
10:30:00 01/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 5,731.00 JPY | -0.85% |
|
-3.97% | +18.53% |
| 09-30 | Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading | MT |
| 09-30 | Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial | MT |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 9,151,024 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 2.27% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 13,057,541 | 12,853,210 | 12,547,445 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 154.51% | -1.56% | -2.38% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 45.4x | 28.8x | 23.5x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.23x | 1.23x | 1.22x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 12.88x | 0.5x | 1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.95x | 1.91x | 1.86x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.78x | 2.68x | 2.55x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 10.2x | 9.28x | 8.69x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 27.8x | 21.3x | 18x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 18.5x | 18.3x | 17.1x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.4% | 5.46% | 5.86% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 215.8 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.57% | 3.64% | 3.76% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 126.3 | 198.7 | 243.8 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 162% | 105% | 88.5% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,703,619 | 4,794,178 | 4,920,458 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,283,686 | 1,384,728 | 1,444,038 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 470,109 | 603,263 | 697,746 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 196,495 | 322,724 | 383,352 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,906,517 | 3,702,186 | 3,396,421 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 5,731.00 | 5,731.00 | 5,731.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 11/05/22 | 11/05/23 | 09/05/24 | 08/05/25 | 13/05/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 45.76x | 2.79x | 10.23x | 3.54% | 58.73B | |
| 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 28.86x | 6.26x | 16.86x | 2.37% | 382.26B | |
| Weighted average by Cap. | 32.31x | 7.64x | 18.76x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
